- In April 2023, the Biomedical Advanced Research and Development Authority (BARDA) partnered with Aptitude Medical Systems, Inc. to accelerate the development of molecular diagnostic tests for COVID-19. These Metrix tests use saliva samples as clinical specimens, enhancing accessibility to high-quality diagnostics
- In April 2021, Quidel Corporation entered a distribution agreement with McKesson Corporation to expand the availability of at-home COVID-19 testing services, boosting the market potential for saliva-based screening tests
- In February 2021, George Mason University in Fairfax began COVID-19 testing using Fluidigm Corporation’s Advanta Dx SARS-CoV-2 RT-PCR Assay on the Fluidigm Biomark HD system
Frequently Asked Questions
The market is segmented based on Global COVID-19 Saliva Screening Test Potential Market Segmentation, By Location (Travel Stations, Sports Arenas, Entertainment Venues, Corporate Campus Environments, Universities and Colleges, Factories, and Others), Technology (Fluorescence-Labeled Antigen/Antibodies Testing, RT-PCR, and CRISPR-Cas9), Mode (Centralized Testing and Decentralized Testing) – Industry Trends and Forecast to 2032
.
The Global Covid 19 Saliva Screening Test Potential Market size was valued at USD 3.13 USD Billion in 2024.
The Global Covid 19 Saliva Screening Test Potential Market is projected to grow at a CAGR of 7.23% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
